ASCO 2024 | Melanoma trials at ASCO 2024: KEYMAKER-U02A, IMC-F106 and SC-682

Meredith McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, TN, gives an overview of key melanoma trials at the 2024 American Society of Clinical Oncology (ASCO) Meeting. The Phase I/II KEYMAKER-U02A trial (NCT04305041) assessed combination therapies for anti-PD-(L)1-refractory melanoma. Patients received either pembrolizumab with quavonlimab and vibostolimab, pembrolizumab with quavonlimab and lenvatinib, or pembrolizumab with ATRA. Findings from the Phase I trial (NCT04262466) assessing IMC-F106C, a novel ImmTAC bispecific protein (PRAME × CD3), in patients with HLA-A*02:01-positive metastatic cutaneous melanoma (mCM) showed the treatment had notable clinical activity. Dr McKean also comments on a Phase 1 trial (NCT03161431) investigating SX-682, a CXCR1/2 inhibitor, combined with pembrolizumab. This interview took place during the 2024 ASCO Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.